Table 1.
Study Cohort Characteristics by Variant of Concern/Variant of Interest
| Characteristics | All | Ancestral | Alpha | Beta | Gamma | Delta | Epsilon | Iota | Omicron | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Na | 58 848 | 5178 | (8.8) | 8729 | (14.8) | 231 | (0.4) | 2103 | (3.6) | 33 115 | (56.2) | 3526 | (6.0) | 638 | (1.1) | 5362 | (9.1) |
| Hospitalized (%)b | 1705 | 117 | (2.3) | 233 | (2.7) | 11 | (4.8) | 112 | (5.3) | 1109 | (3.3) | 74 | (2.1) | 13 | (2.0) | 36 | (0.7) |
| Median time (in days) to hospitalization (IQR) | 6 | (5) | 6 | (5) | 7.5 | (3.25) | 6 | (4.75) | 6 | (4.75) | 5 | (4) | 3.5 | (4) | 7 | (6) | |
| Age (%)b | |||||||||||||||||
| 0–9 | 5661 | 418 | (8.1) | 888 | (10.2) | 22 | (9.5) | 198 | (9.4) | 3412 | (10.3) | 307 | (8.7) | 54 | (8.5) | 362 | (6.8) |
| 10–19 | 8954 | 814 | (15.7) | 1561 | (17.9) | 52 | (22.5) | 272 | (12.9) | 4548 | (13.7) | 590 | (16.7) | 113 | (17.7) | 1004 | (18.7) |
| 20–29 | 12340 | 1053 | (20.3) | 1948 | (22.3) | 51 | (22.1) | 527 | (25.1) | 6485 | (19.6) | 760 | (21.6) | 154 | (24.1) | 1362 | (25.4) |
| 30–39 | 11156 | 984 | (19.0) | 1640 | (18.8) | 39 | (16.9) | 432 | (20.5) | 6285 | (19.0) | 657 | (18.6) | 128 | (20.1) | 991 | (18.5) |
| 40–49 | 8345 | 741 | (14.3) | 1273 | (14.6) | 34 | (14.7) | 317 | (15.1) | 4583 | (13.8) | 524 | (14.9) | 93 | (14.6) | 780 | (14.5) |
| 50–59 | 6012 | 569 | (11.0) | 797 | (9.1) | 22 | (9.5) | 186 | (8.8) | 3529 | (10.7) | 383 | (10.9) | 56 | (8.8) | 470 | (8.8) |
| 60–69 | 3807 | 378 | (7.3) | 389 | (4.5) | 9 | (3.9) | 108 | (5.1) | 2429 | (7.3) | 209 | (5.9) | 25 | (3.9) | 260 | (4.8) |
| 70–79 | 1704 | 139 | (2.7) | 150 | (1.7) | 2 | (0.9) | 33 | (1.6) | 1223 | (3.7) | 62 | (1.8) | 11 | (1.7) | 84 | (1.6) |
| 80–89 | 681 | 60 | (1.2) | 68 | (0.8) | 0 | (0.0) | 22 | (1.0) | 462 | (1.4) | 31 | (0.9) | 3 | (0.5) | 35 | (0.7) |
| 90+ | 222 | 22 | (0.4) | 15 | (0.2) | 0 | (0.0) | 8 | (0.4) | 159 | (0.5) | 3 | (0.1) | 1 | (0.2) | 14 | (0.3) |
| Sex (%)b | |||||||||||||||||
| Female | 28518 | 2410 | (46.5) | 4234 | (48.5) | 104 | (45.0) | 1026 | (48.8) | 16053 | (48.5) | 1666 | (47.2) | 292 | (45.8) | 2733 | (51.0) |
| Male | 29219 | 2595 | (50.1) | 4328 | (49.6) | 123 | (53.2) | 1040 | (49.5) | 16513 | (49.9) | 1739 | (49.3) | 330 | (51.7) | 2551 | (47.6) |
| Other | 58 | 5 | (0.1) | 9 | (0.1) | 0 | (0.0) | 1 | (0.0) | 36 | (0.1) | 2 | (0.1) | 0 | (0.0) | 5 | (0.1) |
| Unknown | 1087 | 168 | (3.2) | 158 | (1.8) | 4 | (1.7) | 36 | (1.7) | 513 | (1.5) | 119 | (3.4) | 16 | (2.5) | 73 | (1.4) |
| Vaccination (%)b | |||||||||||||||||
| No Vaccination to <21 post dose 1 | 44845 | 5100 | (98.5) | 8412 | (96.4) | 221 | (95.7) | 1946 | (92.5) | 23108 | (69.8) | 3438 | (97.5) | 620 | (97.2) | 2000 | (37.3) |
| ≥21 days post dose 1 to <21 days post booster | 12895 | 75 | (1.4) | 309 | (3.5) | 10 | (4.3) | 154 | (7.3) | 9434 | (28.5) | 86 | (2.4) | 18 | (2.8) | 2809 | (52.4) |
| ≥21 days post dose 1 | 1142 | 0 | (0.0) | 2 | (0.1) | 0 | (0.0) | 1 | (0.1) | 565 | (1.7) | 2 | (0.1) | 0 | (0.0) | 553 | (10.3) |
Abbreviation: IQR, interquartile range.
a
Row percentages.
b
Column percentages.